Lasa Supergenerics Ltd (NSE: LASA, BSE: 540702) is a Ratnagiri, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹26 Cr, it ranks #4,390 by market cap among the 6,137 Indian listed companies on FinBizNet, and #58 of 63 in Pharmaceuticals. At ₹4.91 (as of 25 Oct 2026), the share price is 59.2% below its 52-week high of ₹12.04 and 0.0% above its 52-week low of ₹4.91. The share price is down 52.0% over one year and down 29.3% over three months.
| Current Price | ₹4.91 |
|---|---|
| Market Cap | ₹26 Cr |
| NSE Symbol | LASA |
| BSE Code | 540702 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | -0.7 |
| Return on Equity | -51.14% |
| Return on Assets | -9.82% |
| 52-Week Range | ₹4.91 – ₹12.04 |
| 1-Year Price Change | -52.0% |
| 3-Month Price Change | -29.3% |
| Beta (1Y) | 1.1 |
| Dividend Yield | 5.09% |
| Headquarters | Ratnagiri, Maharashtra |
| Website | lasalabs.com |
| Revenue | ₹1 Cr |
|---|---|
| Net Profit | ₹-4 Cr |
| Net Margin | -291.1% |
| EPS (Basic) | ₹0.71 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
1. Active Pharmaceutical Ingredients (API)-This segments engages in the research, manufacture, and marketing of animal and human healthcare products.
1. Active Pharmaceutical Ingredients (API)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Lasa Supergenerics Ltd | ₹26 Cr | -0.7 | -51.14% | ₹1 Cr | -52.0% |
Listed by market capitalisation. Ratios are shown for context only.
Lasa Supergenerics Ltd is trading at ₹4.91, with a market capitalisation of ₹26 Cr.
Lasa Supergenerics Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Lasa Supergenerics Ltd has a P/E of -0.7 and a return on equity of -51.14%.
Lasa Supergenerics Ltd is listed on the NSE under the symbol LASA and on the BSE under the scrip code 540702.
Lasa Supergenerics Ltd's share price is down 52.0% over one year and down 29.3% over three months. Its 52-week range is ₹4.91 to ₹12.04.
In Q1 FY27, Lasa Supergenerics Ltd reported revenue of ₹1 Cr and net profit of ₹-4 Cr, with basic EPS of ₹0.71 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.